2025 年 7 月 25 日 ——基孔肯雅热国内情况点评 要点 事件： 2025 年 7 月，基孔肯雅热在国内外引发广泛关注。截至 7 月 23 日，佛 山全市已累计公开报告基孔肯雅热确诊病例 3645 例。其中顺德区 3317 例，较 前一日增长 383 例。国际方面，法国属地留尼汪岛约三分之一人口感染，印度、 孟加拉国等东南亚国家疫情持续扩散，法国、意大利等欧洲国家也出现输入性病 例及本土传播。世界卫生组织（WHO）警告，全球 119 个国家和地区存在病毒 传播，约 550 万人面临感染风险，可能对卫生系统造成压力。 点评： 国内暂无特效药与疫苗，防蚊灭蚊是防控核心：基孔肯雅热由基孔肯雅病毒 （CHIKV）引起，主要通过伊蚊叮咬传播，其临床特征为急性发热、剧烈关节痛 （可持续数周甚至数月）及皮疹，儿童、老人及免疫低下者风险更高。目前全球 尚无特效治疗药物，也无广泛使用的预防疫苗，临床以对症支持治疗为主，如使 用对乙酰氨基酚退烧等。防控方面，清除蚊虫孳生地、个人防蚊（如使用驱蚊液、 蚊帐）是关键措施。国内广东等地因埃及伊蚊、白纹伊蚊等广泛分布存在潜在传 播风险，需加强监测与公众教育。 血清学检测和病原学检 ...

Core Viewpoint - The epidemic of Chikungunya fever in Guangdong Province remains at a high plateau, indicating a severe situation that requires attention [1]. Summary by Sections Epidemic Situation - As of July 22, 2025, Shunde District in Foshan City reported a total of 2,934 confirmed cases of Chikungunya fever, with a significant increase of 463 cases in just one day [4][5]. - The first report of the epidemic in Shunde was on July 15, 2025, with 478 confirmed cases, showing an increase of over 2,000 cases in just over a week [4]. - The World Health Organization (WHO) reported that 119 countries and regions have identified Chikungunya virus transmission, with approximately 5.5 million people at risk globally, potentially leading to widespread outbreaks [4][5]. Companies Involved in Prevention and Detection - **Runben Co., Ltd. (润本股份)**: A leading domestic company in mosquito repellent products, with a revenue of 440 million yuan in 2024, showing a year-on-year growth of 35.4% and a gross margin of 54.2% [7]. - **Rainbow Group (彩虹集团)**: A well-known pest control company in China, offering a full range of mosquito repellent products that play a crucial role in controlling Chikungunya fever [8]. - **Shanghai Jahwa (上海家化)**: The "Liushen" brand is the top brand in China for mosquito repellent flower water, holding significant brand influence in mosquito prevention and personal care [9]. - **Longyun Group (朗云集团)**: A Hong Kong-listed company that has maintained the number one market share in pest control products for ten consecutive years, with notable products performing well during the epidemic [10]. - **Kangzhi Pharmaceutical (康芝药业)**: Offers a full range of baby and child health protection products, including disinfectants and mosquito repellents, demonstrating expertise in child health protection [11]. - **Shuoshi Gene (硕世纪录物)**: Utilizes gene sequencing technology for Chikungunya fever testing, providing precise diagnostic support for epidemic prevention [12]. - **Da'an Gene (达安基因)**: Provides nucleic acid testing kits for Chikungunya virus, leveraging extensive experience in molecular diagnostics [13]. - **Huiyu Medical (会域医学)**: A leading medical testing institution in China, employing advanced technology for accurate diagnosis of Chikungunya fever [14]. - **Wansheng Biology (万学生物)**: Offers rapid testing solutions for Chikungunya virus, focusing on point-of-care testing [16]. - **Nuo Weisha (诺唯莎)**: Combines molecular design with various heat-start technologies to enhance detection efficiency for mosquito-borne viruses [17].

7月23日，明德生物今日收盘22.03元，上涨2.23%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到132.01倍，创318天以来新低，总市值51.22亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均53.52倍，行业中值37.14倍，明德生物排 名第108位。 武汉明德生物科技股份有限公司的主营业务是体外诊断试剂和诊断仪器的研发、生产、销售和服务。公 司的主要产品是体外诊断试剂和仪器、急危重症信息化解决方案、第三方医学检验服务。 最新一期业绩显示，2025年一季报，公司实现营业收入6996.03万元，同比14.76%；净利润-3662988.06 元，同比-111.43%，销售毛利率16.37%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13明德生物132.0168.740.8851.22亿行业平均 53.5248.844.67111.58亿行业中值37.1437.112.5651.72亿1九安医疗10.9411.060.86184.59亿2英科医疗 12.7713.771.14201.84亿3新华医疗15.2014.091.2497.43亿4奥美医疗15.95 ...

证券代码：002932 证券简称：明德生物 公告编号：2025-036 二、与会计师事务所沟通情况 本次业绩预告未经注册会计师预审计。 武汉明德生物科技股份有限公司 2025 年半年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 6 月 30 日 2、 预计净利润为正值且属于下列情形之一： □ 扭亏为盈 □ 同向上升 同向下降 | 项目 | 本报告期 | | 上年同期 | | | --- | --- | --- | --- | --- | | 归属于上市公司股 | 盈利：1,000 | 万元—1,500 万元 | 盈利：6,516.26 | 万元 | | 东的净利润 | 比上年同期下降：76.98%—84.65% | | | | | 归属于上市公司股 | | | | | | 东的扣除非经常性 | 亏损：3,500 | 万元—4,500 万元 | 亏损：2,882.27 | 万元 | | 损益后的净利润 | | | | | | 基本每股收益 | 0.05 元/股—0 ...

Company Overview - Mingde Biological Technology Co., Ltd. specializes in the research, production, sales, and service of in vitro diagnostic reagents and instruments, as well as information solutions for critical care and third-party medical testing services [1] - The company's main products include in vitro diagnostic reagents and instruments, critical care information solutions, and third-party medical testing services [1] Financial Performance - For Q1 2025, the company reported revenue of 69.96 million yuan, representing a year-on-year increase of 14.76% [1] - The net profit for the same period was -3.66 million yuan, showing a year-on-year decline of 111.43% [1] - The gross profit margin for the company stood at 16.37% [1] Market Position - As of July 11, the company's stock closed at 20.15 yuan, down 1.32%, with a rolling price-to-earnings (PE) ratio of 120.74 times [1] - The total market capitalization of the company is 4.685 billion yuan [1] - In comparison to the industry, the average PE ratio for the medical device sector is 52.06 times, with a median of 37.22 times, placing Mingde Biological at the 108th position in the industry [1][2] Shareholder Information - As of June 30, 2025, the number of shareholders for Mingde Biological is 24,838, a decrease of 200 from the previous count [1] - The average market value of shares held by each shareholder is 352,800 yuan, with an average holding of 27,600 shares [1]

Group 1 - The core viewpoint is that Mingde Biological has experienced significant growth in market capitalization and development in the POCT rapid diagnostic field since its listing, but its operational performance has shown notable fluctuations in recent years [1][3]. - Mingde Biological's main business includes the independent research, production, and sales of POCT rapid diagnostic reagents and testing instruments, with in vitro diagnostic products and solutions accounting for the highest revenue share at 62.89% [3]. - The company achieved a cumulative profit growth of 21.33% from a net profit of 0.61 billion yuan in 2018 to 0.75 billion yuan in 2024, with no annual losses recorded since its listing [3]. Group 2 - Revenue analysis shows that Mingde Biological's revenue peaked at 9.59 billion yuan in 2020 but fell to 3.50 billion yuan in 2024, indicating a significant decline post-pandemic [3]. - Profit analysis reveals that the net profit reached a high of 4.69 billion yuan in 2020, dropping to 0.75 billion yuan in 2024, reflecting a substantial adjustment after the pandemic peak [3]. - Since its listing, Mingde Biological's market capitalization has increased by 142%, peaking at 150.45 billion yuan in May 2022, but has since decreased by 68.47% to 47.43 billion yuan as of July 2023 [5].

证券代码：002932 证券简称：明德生物 公告编号：2025-035 武汉明德生物科技股份有限公司 关于公司参与设立投资基金暨关联交易的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、投资基金概述 武汉明德生物科技股份有限公司（以下简称"公司"）于 2023 年 6 月 20 日 召开第四届董事会第五次会议，审议通过了《关于参与投资私募股权投资基金暨 关联交易的议案》，同意公司与明熙创业投资管理（武汉）有限公司（以下简称 "明熙创投"）、陈莉莉女士、拉萨君祺企业管理有限公司（以下简称"拉萨君 祺"）投资设立武汉市明君合纵创业投资基金合伙企业（有限合伙）（以下简称 "基金"），该基金认缴出资总额为 23,500 万元人民币，其中公司以自有资金认 缴出资 17,500 万元人民币。 2023 年 7 月 19 日，基金完成备案。 2023 年 9 月 22 日，公司召开第四届董事会第八次会议，审议通过了《关于 控股子公司参与投资私募股权投资基金暨关联交易的议案》，同意公司控股子公 司广东明志医学检验实验室有限公司（以下简称"广东明志"）作为有限合伙 ...

Core Viewpoint - The in vitro diagnostics sector experienced a slight increase of 0.24% on July 4, with a net outflow of funds amounting to 42.33 million [1] Group 1: Market Performance - A total of 18 stocks in the sector saw gains, while 49 stocks declined [1] - The top decliners included Dongfang Ocean (-6.51%), Xilong Scientific (-3.81%), and Nearshore Protein (-2.54%) [1][1] Group 2: Stock Performance - Notable gainers included: - Hotgen Biotech with a price of 194.81 and an increase of 20.08%, attracting a net fund inflow of 2.125 million [1] - Saily Medical at 21.08, up 10.02%, with a net inflow of 1.758 million [1] - Zhongyuan Union at 25.87, rising 9.99%, with a net inflow of 1.38 billion [1] - Decliners included: - Botao Biotech at 37.34, down 3.38%, with a net outflow of 1.087 million [1] - Maike Biotech at 7.99, down 2.44%, with a net inflow of 176.92 thousand [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Mingde Biological Technology Co., Ltd., particularly its stock performance and valuation metrics [1][2] - As of July 3, the closing price of Mingde Biological was 20.7 yuan, reflecting a 2.48% increase, with a rolling PE ratio of 124.04, marking a new low in 17 days, and a total market capitalization of 4.813 billion yuan [1] - The average PE ratio for the medical device industry is 51.48, with a median of 36.88, positioning Mingde Biological at the 108th rank within the industry [1][2] Group 2 - As of the first quarter of 2025, six institutions held shares in Mingde Biological, including four funds and two insurance companies, with a total holding of 13.8456 million shares valued at 250 million yuan [1] - The main business of Mingde Biological includes the research, production, sales, and service of in vitro diagnostic reagents and instruments, as well as solutions for critical care information and third-party medical testing services [1] - The latest financial report for the first quarter of 2025 shows that the company achieved a revenue of 69.9603 million yuan, a year-on-year increase of 14.76%, while the net profit was -3.662988 million yuan, a year-on-year decrease of 111.43%, with a gross profit margin of 16.37% [1]

2、董事长好!请问董事长，股票一直在净资产下面，公司 近期是否有计划提升市值计划。 答：尊敬的投资者，您好！公司于 2025 年 4 月 25 日披露 了《2025 年度估值提升计划》，公司拟通过提升经营效率、 积极寻求投资并购、持续现金分红、适时开展中长期激励计划、 优化信息披露与投资者关系管理等举措，提升公司投资价值和 股东回报能力，推动公司投资价值合理反映公司质量，增强投 资者信心、维护全体股东利益，促进公司高质量发展。感谢您 的关注！ 3、陈董您好，2023 年检测业务萎缩，公司急需新的增长 点， 投资者普遍关心公司的创新业务扩展，比如通过并购快 速获取技术和市场，增加市占率， 请问公司是否切入传染病 产业链上的疫苗或创新药领域，以应对后疫情时代的业绩挑 战。 答：尊敬的投资者您好！目前公司暂未切入传染病产业链 的疫苗或创新药领域。公司正聚焦现有核心技术优势，从两方 证券代码：002932 证券简称：明德生物 武汉明德生物科技股份有限公司投资者关系活动记录表 编号：2025-001 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访 业绩说明会 ...